ASH 2025: Interpreting Rapid Change Across Hematology
Returning from the American Society of Hematology Annual Meeting in Orlando, one message was clear:...
Posts about
Oncology
Targeted Indication Selection Using Simon 2-Stage Design
Learn how Veristat’s biostatistics and strategic consulting teams were able to work with a...
Advancing Dose Escalation Strategies with Bayesian Modeling
Learn how our biostatistics and strategic consulting teams collaborated with our biotechnology...
3 Reasons Why You Need to Consider a CRO That Excels in Oncology Regulatory Publishing
In oncology drug development, every day counts. Patients are waiting, trials are complex, and the...
Advancing Oncology Innovation with Adaptive Trial Designs
Learn how our strategic and regulatory team was able to work with a biopharmaceutical sponsor to...
Single-Arm Studies: A Strategic Path to Oncology Drug Approval
In oncology drug development, randomized controlled trials (RCTs) are the gold standard for...
Trends in Oncology Regulation: FDA Draft Guidance on OS and Radiopharmaceuticals
Over the past two decades, the FDA has steadily increased the number of guidance documents it...
Reflections from ASCO 2025
Clinical Impact, Technology Innovation, and Emerging Advances in Cell and Vaccine-Based Oncology
Project Optimus Explained: Why the FDA is Shifting Away from Maximum Tolerated Dose in Oncology
Historically, oncology drug development followed a straightforward principle: identify the highest...
Top 3 Tips for Choosing the Right Oncology CRO
The decision to partner with a Clinical Research Organization (CRO) is never taken...